Form 4: Harvard Bioscience Director Loewald Receives Stock Award
SEC Form 4 Filing
Director Thomas W. Loewald of Harvard Bioscience, Inc. acquired 45,872 shares of common stock through a restricted stock unit award on May 21, 2024.
Summary
- On May 21, 2024, Thomas W. Loewald, a director of Harvard Bioscience, Inc., acquired 45,872 shares of common stock.
- This acquisition was through a restricted stock unit award.
- The award vests fully on the earlier of the next Annual Meeting of Stockholders after May 14, 2024, or May 21, 2025.
- Following the transaction, Loewald beneficially owns 295,311 shares of Harvard Bioscience common stock, including the newly awarded shares and 249,439 previously held shares.
Sentiment
Score: 7
Explanation: The document reflects a standard transaction of stock award to a director, which is generally viewed positively as it aligns management's interests with shareholders. There are no explicit negative indicators.
Positives
- The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.
Future Outlook
The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedule of the stock award provides a timeline for the director's continued involvement and alignment with the company's success.
Industry Context
This type of stock award is a common practice in corporate governance to incentivize and retain key personnel, aligning their interests with those of the shareholders.
Comparison to Industry Standards
- Stock awards are a typical component of executive compensation packages in the bioscience industry.
- Companies like Thermo Fisher Scientific and Danaher Corporation also utilize stock awards as part of their compensation strategy to align executive interests with shareholder value.
- The vesting schedule is fairly standard, with vesting tied to continued service or specific performance milestones.
Stakeholder Impact
- Shareholders may view the stock award positively as it aligns the director's interests with the company's performance.
- Employees may see this as a sign of stability and commitment from the leadership.
Key Dates
| Date | Description |
|---|---|
| 05/14/2024 | Date referenced for the vesting condition of the restricted stock units. |
| 05/21/2024 | Date of the transaction where Loewald acquired 45,872 shares of common stock. |
| 05/21/2025 | Latest date for full vesting of the restricted stock units. |
| 05/23/2024 | Date of the form filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.